CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired Vigene Biosciences, Inc. for $323.9 million, net of $2.7 million cash (includes $34.5 million contingent consideration), a transaction completed in June 2021, structured as all cash.
Vigene Biosciences, Inc. operates in Manufacturing Support — gene therapy CDMO, is based in United States (Rockville, Maryland). Vigene Biosciences was a gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.
The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The preliminary purchase price of Vigene was $323.9 million, net of $2.7 million in cash.
Manufacturing Support segment, Biologics / CDMO
The acquisition enables clients to seamlessly conduct analytical testing, process development, and manufacturing for advanced modalities with the same scientific partner. The preliminary purchase price of Vigene was $323.9 million, net of $2.7 million in cash, and includes $34.5 million of contingent consideration.Charles River FY2021 10-K, Business Acquisitions note
Advisory firms were not disclosed for this transaction.